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Abstract 
The classical regard of lipid droplets as mere static energy-storage organelles has 
evolved dramatically. Nowadays these organelles are known to participate in key 
processes of cell homeostasis, and their abnormal regulation is linked to several 
disorders including metabolic diseases (diabetes, obesity, atherosclerosis or hepatic 
steatosis), inflammatory responses in leukocytes, cancer development and 
neurodegenerative diseases. Hence, the importance of unravelling the cell mechanisms 
controlling lipid droplet biosynthesis, homeostasis and degradation seems evident. 
Phospholipase A2s, a family of enzymes whose common feature is to hydrolyze the 
fatty acid present at sn-2 position of phospholipids, play pivotal roles in cell signaling 
and inflammation. These enzymes have recently emerged as key regulators of lipid 
droplet homeostasis, regulating their formation at different levels. This review 
summarizes recent results on the roles that various phospholipase A2 forms play in the 
regulation of lipid droplet biogenesis under different conditions. These roles expand the 
already wide range of functions that these enzymes play in cell physiology and 
pathophysiology.  
 
Abbreviations:  LD: lipid droplet;  PLA2: phospholipase A2; cPLA2: cytosolic  
phospholipase A2;  iPLA2: Ca
2+-independent phospholipase A2; sPLA2: secreted 
phospholipase A2; Lp-PLA2: lipoprotein-associated PLA2; PC: phosphatidylcholine;  
lysoPC: lysophosphatidylcholine; PE: phosphatidylethanolamine; lysoPE: 
lysophosphatidylethanolamine; PI: phosphatidylinositol;  PA: phosphatidic acid;  
lysoPA: lysophosphatidic acid; TAG: triacylglycerol;  CE: cholesteryl esters; AA: 
arachidonic acid; HCV: hepatitis C virus; LDL: low-density lipoprotein; ox-LDL: 
oxidized low-density lipoprotein; PAF, platelet-activating factor.  
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1. Introduction  
Lipid droplets (LDs) are organelles present practically in all cell types. All LDs are 
spherical particles with a surface composed of a phospholipid monolayer decorated by a 
variety of proteins that encases a neutral lipid core consisting primarily of 
triacylglycerol (TAG) and cholesteryl esters (CE). Over a hundred distinct molecular 
species of phospholipids have been identified in the LD phospholipid monolayer [1-3]. 
In mammalian cells and yeast, phosphatidylcholine (PC) is the most abundant  
phospholipid, comprising up to 60% of total phospholipid content, followed by 
phosphatidylethanolamine (PE) (24%) and phosphatidylinositol (PI) (8%) [4].  
Specific populations of proteins that are more or less tightly bound to the LD 
surface play different roles in LD biogenesis, trafficking and mobilization. Prominent 
proteins of mammalian LDs are the so-called PAT family, which includes perilipin, 
adipophilin and TIP47 (Tail-Interacting Protein of 47 KDa) [5]. Additionally, numerous 
enzymes related to lipid metabolism have been described, including adipose triglyceride 
lipase, hormone-sensitive lipase, CGI-58 (comparative gene identification-58) [6,7], 
CTP:phosphocholine cytidylyltransferase [8], lipin-1 [9,10], and, group IVA 
phospholipase A2, (cytosolic phospholipase A2α, cPLA2α) [11,12]. 
LD biogenesis needs to be contemplated in the context of the synthesis and 
turnover of its major components: TAG and CE. These neutral lipids can be formed 
using fatty acids arising from various origins, i.e. exogenous sources, other cellular 
compartments, or via stimulation of the de novo fatty acid biosynthetic pathway. Once 
synthesized, the neutral lipids are first clamped between the two layers of the 
endoplasmic reticulum membrane. Phospholipid bilayers can accommodate about 3% 
TAG or 5% CE, on a molar basis, before the neutral lipid phase separates to form 
spherical domains of about 25–28 nm diameter that remain sandwiched between the 
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bilayer leaflets [13]. Such TAG microdomains are probably the precursors of the LD 
that are released from the endoplasmic membrane to the cytosol; however there is much 
controversy about the origin of the LDs and various hypotheses have been put forward 
to explain the experimental evidence. These have recently been reviewed in detail [14]. 
LD number and size varies dynamically from one cell type to another, or among 
cells of the same population, and the activation state of the cells appears to be a key 
factor [15,16]. It has recently been shown in hepatocytes that the LDs within a given 
cell or among cells of the same tissue show a remarkable heterogeneity [17]. Thus it has 
been suggested that the existence of cells containing high lipid levels within a cell 
population could potentially reduce lipotoxicity to the average cell without impairing 
overall lipid homeostasis [17].  
The impressive number of recent studies and review articles dealing with LDs, 
illustrates the dramatic change in the way these organelles are currently perceived. From 
being regarded as mere storage depots for metabolic fuel and membrane-building 
blocks, LDs are now recognized as key players in the cellular regulation of lipid 
homeostasis, signaling, protein sorting, extra- and intracellular trafficking, and gene 
transcription regulation [14,18,19]. Furthermore, the formation of LDs may also 
constitute a sign of stress and of apoptotic cell death [20].  
 
2. Phospholipase A2 enzymes 
2.1. Classification 
Phospholipase A2 (PLA2) enzymes constitute an heterogeneous group of  proteins which 
have been systematically classified according to sequence homology criteria. The latest 
update to this classification, published in 2011 [21], included 16 groups, most of them 
with several subgroups, comprising more than 30 proteins (Table I). Only PLA2s whose 
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nucleotide sequence has been determined are included in the classification. Although 
the common feature of all these proteins is that they possess PLA2 activity, that is, they 
hydrolyze the fatty acid at the sn-2 position of glycerophospholipids, recent additions to 
the classification display very low PLA2 activity or no PLA2 activity at all. Also some 
members of the PLA2 superfamily frequently display other activities in addition to 
PLA2, such as phospholipase A1, lysophospholipase, transacylase or TAG lipase 
[21,22]. 
There is an alternative PLA2 classification, sometimes more useful, which 
groups these enzymes into 6 major classes on the basis of biochemical commonalities 
and/or cell regulation properties. These are the Ca2+-dependent cytosolic PLA2s 
(cPLA2), the Ca
2+-dependent secreted PLA2s (sPLA2), the Ca
2+-independent cytosolic 
PLA2s (iPLA2), the platelet-activating factor acetyl hydrolases (PAF-AH), the 
lysosomal PLA2 (LPLA2) and the adipose-specific PLA2 (AdPLA) [21,22]. Note that 
despite its evident usefulness, this classification is not devoid of inconsistencies, e.g. 
despite being referred to as secreted enzymes, some sPLA2s may indeed act inside the 
cells, cPLA2γ is grouped among the Ca2+-dependent cytosolic enzymes despite it being 
completely Ca2+-independent, etc.  
Of these classes, the first two have been repeatedly implicated in AA 
mobilization leading to eicosanoid synthesis in response to a variety of 
immunoinflammatory stimuli [23-25]. The pivotal enzyme is the cPLA2α, an enzyme 
that exhibits marked preference towards AA-containing phospholipids [26]. Some 
sPLA2 enzymes, i.e. those from groups IIA, V and X may amplify the cPLA2α-mediated 
AA release and eicosanoids production either directly by effecting the AA release 
themselves or by modulating the extent of cPLA2α activation [27-29]. cPLA2α-
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independent AA release and eicosanoid response by group V and group X sPLA2s 
acting directly on the extracellular surface is also known to occur in some instances 
[30]. There is no clear evidence that iPLA2 enzymes play major effector roles in AA 
mobilization in response to most stimuli although in some circumstances and in 
response to specific agonists, these enzymes may serve such role [21,31]. iPLA2 
enzymes may also participate in the formation of cellular AA pools by providing 
lysophospholipid acceptors for AA reacylation reactions [32-34].  
The presence of PLA2 enzymes in practically all cells and tissues examined 
stresses the important roles they play in many physiological and pathophysiological 
processes. A number of comprehensive reviews have recently been published covering 
various aspects of PLA2 biochemistry, including structure, catalysis, cellular regulation 
and physiological/pathophysiological functions [21,22,35-37], and the reader is kindly 
referred to them for further details.  
 
2.2. PLA2 and lipid droplets 
Recent evidence suggests that LDs may function as intracellular sites for eicosanoid 
biosynthesis. LDs of different cell populations such as eosinophils, macrophages, 
neutrophils or mast cell avidly incorporate exogenous AA. Lipid analyses of LDs 
isolated from blood leukocytes have shown that AA is mainly esterified in 
phospholipids [38], whereas in mast cells and macrophages it is found primarily in 
neutral lipids [39]. Whether these differences in localization have a physiological 
consequence or are due to other factors, i.e. differences in the total content of AA 
present in the cells [40], is unknown. 
Several enzymes implicated in the biosynthesis of eicosanoids have been found 
associated with LDs under activation conditions, including cPLA2α [11,12]. 
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Extracellular signal-regulated kinases-1 and -2, which can phosphorylate and activate 
cPLA2α, have also been found in LDs [41], as well as the major AA-converting 
enzymes 5-lipoxygenase, 15-lipoxygenase, 5-lipoxygenase-activating protein, and 
cyclooxygenase-2 [15,42]. Lipin-1, a phosphatidic acid phosphatase that acts as an 
upstream regulator of cPLA2α and attendant AA release and eicosanoid production [43-
45], has also been found in LDs [9]. 
 Aside from the role of LDs as platforms for compartmentalized regulation of  
AA mobilization and eicosanoid synthesis, various PLA2 forms have also emerged as 
critical regulators of the biogenesis of LDs. PLA2s may act at several levels, namely (i) 
as providers of free fatty acids from membrane phospholipids for the synthesis of 
neutral lipids [46-48], (ii) as modifiers of phospholipid-containing particles to facilitate 
their uptake and internalization by cells [49,50], (iii) as generators of metabolites that 
may control LD formation [51], and (iv) as direct regulators of the formation of the 
organelle [52-54].  
 
3. cPLA2 
To date, 6 cPLA2s have been identified in mammals and classified as group IV PLA2s. 
These enzymes possess a high molecular weight (61-114 kDa) and, with the exception 
of cPLA2γ, a C2 domain at their N-terminal region which binds Ca2+, allowing these 
enzymes translocate to intracellular membranes. Contrary to sPLA2s, only micromolar 
concentration of Ca2+ are required for activity [21,22,26]. 
The best characterized of these enzymes is group IVA PLA2 or cPLA2α, which 
may further require phosphorylation by several kinases and association with 
phosphoinositides or ceramide-1 phosphate for full activation [55]. After stimulation of 
the cells with a variety of agonists, the enzyme translocates to multiple intracellular 
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compartments, including the nuclear envelope, Golgi, endoplasmic reticulum, 
phagosomes, plasma membrane and LDs [11,12,22,26,35,56]. 
 
3.1. Mechanisms of LD biogenesis involving cPLA2α 
The most accepted, albeit not the only, hypothesis for the biogenesis of LDs proposes 
that these organelles are generated in between the two leaflets of the smooth 
endoplasmic reticulum, and bud out to the cytoplasm after a very tightly regulated 
process which includes generation of free fatty acids, thioesterification of the latter with 
CoA, neutral lipid synthesis, remodeling of endoplasmic reticulum membrane 
phospholipids, and synthesis of new phospholipids and LD-associated proteins [14].  
While various cellular PLA2s may contribute to generate the pool of free fatty acids 
initially needed for LD synthesis, strong evidence is emerging that the PLA2 form that is 
centrally involved in the remodeling of endoplasmic reticulum phospholipids and LD 
expansion processes involving deacylation/reacylation reactions is the cPLA2α 
[14,57,58] (Fig. 1). 
DGAT and ACAT, the terminal enzymes for TAG and CE biosynthesis, are 
homogeneously distributed along the endoplasmic reticulum and are able to synthesize a 
large amount of neutral lipid in response to different situations such as external lipid 
overload, endoplasmic reticulum stress or cellular activation [59]. Initially, the neutral 
lipids formed can be accommodated into the hydrophobic space between the two 
leaflets of the endoplasmic reticulum up to a point where the two leaflets of the 
endoplasmic reticulum separate, and TAG and CE become sequestered inside a 
phospholipid monolayer to form a cytoplasmic LD [13,14,60]. Small amounts of 
phospholipid are required for LD monolayer expansion, but a tight regulation of the 
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ratio of phospholipid to neutral lipid in LDs is essential to maintain the round shape and 
biophysical properties of the nascent organelle [4]. 
By controlling the ratio of phospholipid to lysophospholipid in the endoplasmic 
reticulum and Golgi complex, PLA2 enzymes determine the shape and curvature of the 
membranes of these organelles, and allow the proper execution of a number of events 
such as membrane tubule formation in the Golgi, cargo delivery from the endoplasmic 
reticulum to the Golgi, or membrane fusion processes [61-63].  Thus cPLA2α may exert 
similar regulatory effects on the membranes of the smooth endoplasmic reticulum at the 
time that neutral lipid concentration reaches its critical concentration in between the 
leaflets. As a matter of fact, inhibition of cPLA2α activity by various means does not 
change the cellular levels of neutral lipid but results in distorted  endoplasmic reticulum 
membranes with tubulovesicular structure [52].  
The nascent LD needs a local positive membrane curvature in the endoplasmic 
reticulum membrane baseline to grow up. The normal endoplasmic reticulum membrane 
is composed primarily of phosphatidylcholine (PC), which presents a cylindrical shape 
and generates a neutral curvature, and to a lesser extent, phosphatidylethanolamine 
(PE), which generates a slight negative curvature [4, 18]. Biophysical determinations 
have unveiled that accumulation of lysophospholipids with a wedge shape conformation 
such as lysoPC, lysoPE and, especially, lysoPA, generates a local positive membrane 
curvature, beneficial in terms of nascent LD budding [4,14,18,58,64-66]. Since 
lysophospholipids are generated by PLA2s, the key role that cPLA2α appears to play in 
these stages of LD formation can be explained [20,46,52-54] (Figure 1). 
Once the required positive curvature at the LD baseline is generated, more 
neutral lipids can be accommodated inside the phospholipid monolayer, either 
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synthesized in the endoplasmic reticulum or directly in the forming LD, where the 
enzymes necessary for TAG and CE biosynthesis are localized.  This is accompanied by 
the synthesis of phospholipid to maintain the appropriate phospholipid to neutral lipid, 
in a process occurring via both the de novo phospholipid biosynthesis and fatty acid 
recycling by the Lands pathway [8,14], a route in which PLA2 enzymes are essential 
[36,55]. In this regard, the PC molecules on the LD surface are particularly enriched in 
monounsaturated fatty acids, something that does not apply to the PC molecules at the 
endoplasmic reticulum [4], and highlights the important role of phospholipid fatty acid 
recycling to achieve the proper phospholipid composition of  LDs at this stage. 
Once the LD buds from the endoplasmic reticulum membrane, conversion of the 
conical lysophospholipids into cylindrical phospholipids is necessary to establish a 
neutral curvature that confers stability and protects the hydrophobic core from lipolysis. 
In this stage, participation of lysophospholipid acyltransferases using acyl-CoA as 
donor are the essential enzymes [14,58]. Some of these enzymes have also been found 
associated with LDs [4,67]. 
Finally, before LD is completely formed, a local negative curvature in the 
baseline of the endoplasmic reticulum membrane is required [14,58]. This is promoted 
by the accumulation of PA, which induces a spontaneous strong negative curvature 
[18,68] (Fig. 1). PA is thought to be generated primarily by phospholipase D [69,70], 
but achieving the optimal levels of this metabolite may also involve the participation of 
the PA phosphatase lipin-1 [9,10]. Inhibition of lipin-1 results in LD fragmentation and 
reduced size and number of LDs without changes in total TAG content [9,10]. While 
some of these effects are likely due to modification of cellular PA levels, lipin-1 is also 
known to regulate cPLA2α activation [9], which raises the possibility that the latter 
enzyme may also be involved in the regulation of  these events. 
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3.2. Pathways leading to cPLA2α activation that impact on LD 
formation. 
Recent studies have suggested that cPLA2α activation by phosphorylation is necessary 
for LD formation [20,46,52-54]. The relevant phosphorylation with regard to LD 
formation is the one that occurs at Ser505, catalyzed by different members of the 
mitogen-associated protein kinase (MAPK) family of enzymes [55]. Depending on cell 
type and stimulus, this phosphorylation is carried out by the extracellular-regulated 
kinases p42 and p48, p38, and/or SAPK/JNK [55]. This phosphorylation occurs much 
before the cells start making LDs in response to stimulation and its inhibition strongly 
blocks LD formation [20,46,52-54].  
 cPLA2α phosphorylation at Ser505 in cells subjected to different stress 
conditions appears to be necessary and sufficient for LD formation even at Ca2+ levels 
similar to those found in unstimulated cells [46]. This is consistent with results showing 
that pathogens such as bacteria, fungi or virus, which are recognized by Toll-like 
receptors and activate MAPK signaling pathways and cPLA2α in inflammatory cells in 
the absence of sustained intracellular Ca2+ elevations [29,71,72], are strong inducers of 
LD formation in these cells [15,64,73-75]. This LD induction is accompanied by the 
translocation of cPLA2α to the LD surface, an event that  may serve to modulate and/or 
amplify the inflammatory response, as it allows the enzyme to reach the AA-containing 
phospholipids on the LD surface [12,15]. This translocation is likely necessary as well 
to regulate the biogenesis of the organelle itself, as discussed in the previous section. 
Coincidentally, phosphorylation of cPLA2α on Ser505 is also required for translocation 
of the enzyme to phagosomes in macrophages responding to phagocytic stimuli [56]. 
Since a tight association between LDs and phagosomes appears to exist in 
immunoinflammatory cells [64], it is possible that cPLA2α plays similar regulatory 
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roles for both LD formation and phagosome maturation  in cells involved in innate 
immunity and inflammation. 
Although the addition of serum to serum-starved cells leads to the rapid 
activation of all three major MAPK family members, namely, p44/p42, p38, and JNK, 
only JNK activation is involved in cPLA2α phosphorylation at Ser505 [52]. Moreover, 
serum-induced LD formation triggers the activation of ceramide kinase, leading to 
increased levels of ceramide 1-phosphate, which in turn regulates the phosphorylation 
activation of cPLA2α [53]. Interestingly, down-regulation of ceramide kinase blunts not 
only cPLA2α phosphorylation and LD formation but also JNK activation [20,53], 
suggesting that, with independence of any direct effect of ceramide 1-phosphate on 
cPLA2α [76], the lipid may also affect other events that lie well upstream of the 
phospholipase. 
In studies with human monocytes, it was found that not only JNK, but also p38 
is required for the full phosphorylation activation of cPLA2α and subsequent LD 
formation [54]. Inhibition of one of these kinases but not the other, reduced but not 
abolished cPLA2α phosphorylation and LD formation, and simultaneous inhibition of 
both kinases was required for complete blockade of  the responses [54]. Since both JNK 
and p38 regulate the phosphorylation of cPLA2α at the same residue, these data suggest 
the participation of an intermediate kinase, activated by both JNK and p38, which 
would be the one that directly phosphorylates cPLA2α at Ser505 and facilitates LD 
synthesis An analogous mechanism for the phosphorylation activation of cPLA2α by 
two distinct MAPK pathways has been reported in cardiomyocytes stimulated with 
ATP, where it was found that blockade of mitogen and stress-activated kinase-1, a 
kinase that is phosphorylated/activated by both p38 and p42/p44, resulted in inhibition 
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of cPLA2α phosphorylation activation and of attendant cellular responses [77].  
In some cellular systems, it has been reported that the regulatory effect of 
cPLA2α on LD formation is not exerted directly, but rather occurs after formation of  
downstream metabolites, i.e. eicosanoids generated by oxygenation of the cPLA2α 
product free AA [78]. However, when added exogenously, the free fatty acid is able to 
induce significant LD formation in cells in the presence of cyclooxygenase and 
lipoxygenase inhibitors [38,39,52,54]. Importantly, this process occurs in a cPLA2α-
dependent manner, because blockade of the enzyme strongly inhibits LD formation 
[52,54]. Moreover, free AA itself induces the phosphorylation activation of cPLA2α 
[11,54], thereby promoting more AA mobilization. A remarkable positive loop of 
activation would therefore be established that results in optimal LD formation.  
 
3.3. cPLA2α role in LD formation in macrophages exposed to modified 
LDL 
Circulating modified LDL, a major risk for the development of atherosclerosis, is taken 
up by macrophages and delivered to lysosomes, where part of its CE content is 
degraded by an acid lipase, and the resulting free cholesterol utilized for membrane 
synthesis. When the amount of free cholesterol is excessive it is re-acylated by ACAT 
and stored in cytoplasmic LDs. Cells use this energy-expensive mechanism to avoid 
lipotoxicity, which is a major cause of macrophage apoptosis and atherosclerosis 
progression [79,80].  
It is noteworthy that the fatty acid composition of foam cells, containing 
primarily oleic acid, differs from that of LDLs, in which linoleic acid predominates 
[47]. This finding constitutes a strong indication that a significant part of the acyl-CoA 
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pool that is utilized to reacylate excess free cholesterol for LD storage must come from 
endogenous sources [47]. Studies aimed at delineating the intracellular sources of this 
fatty acyl-CoA in ox-LDL-treated macrophages came up with the finding that methyl 
arachidonoyl fluorophosphonate, a dual inhibitor of both cPLA2 and iPLA2 enzymes, 
but not bromoenol lactone, an iPLA2 inhibitor [81], blocked CE synthesis, thus pointing 
to the involvement of a cPLA2 form, most likely cPLA2α [47]. Independent studies had 
shown that macrophage treatment with oxLDL does induce the activation of cPLA2α 
and subsequent release of eicosanoids [82]. 
Two mechanisms have been proposed for the regulation of cPLA2-mediated CE 
formation and subsequent LD formation in ox-LDL-treated macrophages. The first one 
is the activation of the de novo pathway for ceramide synthesis. Elevated intracellular 
levels of ceramide and its phosphorylated product ceramide 1-phosphate are known to 
induce cPLA2α activation [76,83,84]. Murine macrophages increase their ceramide 
levels after exposure to ox-LDL without changes in sphingomyelin levels, suggesting 
activation of ceramide synthesis de novo, and inhibition of this pathway with fumonisin 
B1 significantly reduces CE synthesis [85,86].   
The second route that may regulate the cPLA2α-mediated CE formation in ox-
LDL-treated macrophages is the availability of the oxidized fatty acid 13-
hydroxyoctadecadienoic acid (13-HODE), formed by oxidation of linoleic acid, the 
major fatty acid in LDL. 13-HODE can be released from ox-LDL in atherosclerotic 
lesions via lipoprotein-associated PLA2 (group VIIA PLA2) [87]. 13-HODE has been 
shown to activate cPLA2α by favoring translocation of the enzyme to the membrane, 
where its substrate resides [47,88]. This effect may be mediated by the anionic character 
of 13-HODE, which facilitates cPLA2α interaction with membranes, as has been 
reported with other anionic lipids [55,89,90] or perhaps also because 13-HODE 
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incorporation into membranes might affect their physical properties, increasing the 
susceptibility of membrane phospholipids to cPLA2α [88]. Other major components of 
ox-LDL such as 7-ketocholesterol or 25-hydroxycholesterol did not mimic the effects of 
13-HODE [88]. 
 
3.4. cPLA2α role in neutral lipid accumulation in liver 
Studies on the regulation of LD synthesis and accumulation in the liver are of great 
pathophysiological interest, owing to the essential role of this organ in neutral lipid 
synthesis and accumulation, lipoprotein assembly and secretion and cholesterol 
biosynthesis. Abnormal LD formation in liver appears to be intimately linked with a 
number of  pathologies, including steatosis, steatohepatitis, cirrhosis, and hepatitis C 
virus infection [91-93].  
Studies using cPLA2α-/- mice have shown that this enzyme is required for TAG 
deposition in liver in animals fed a high-fat diet, thus suggesting that blockade of 
cPLA2α protects from hepatic steatosis under these conditions [94]. TAG blood levels 
were found to be similar in both cPLA2α+/+ and cPLA2α-/- mice; however, PGE2 levels 
were strongly reduced in the cPLA2α-/- animals, both under normal and high-fat diet 
[94]. PGE2 is known to induce TAG accumulation in liver, acting via hepatocyte surface 
receptors [78], and to suppress TAG-rich VLDL secretion, resulting in its accumulation 
inside the hepatocyte [95]. Thus cPLA2α-mediated release of AA and its conversion 
into PGE2 via COX-2 may constitute a straightforward pathway through which the 
phospholipase regulates in vivo TAG accumulation in liver cells [94].  
The life cycle of hepatitis C virus (HCV) appears to be tightly related to 
hepatocyte LDs and VLDL secretion [96], hence, the PLA2-regulated LD formation 
could be exploited as a possible therapeutic strategy to manage HCV infection [97,98]. 
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HCV takes advantage of the host cell machinery leading to LD formation, including 
cPLA2α [74]. In accord with this, inhibition of cPLA2α with the selective inhibitor 
pyrrophenone results in dramatic decreases in both LD formation and HCV infectivity 
[74]. Interestingly a second cPLA2 form, cPLA2γ, also appears to be involved in HCV 
replication and assembly, and its down-regulation also results in decreased HCV 
infectivity [99]. This effect of cPLA2γ is thought to occur via regulation of membranous 
web formation, an endoplasmic reticulum-derived structure with unique shape and 
curvature that is essential in HCV replication and assembly [100]. The finding that 
cPLA2γ is an endoplasmic reticulum-associated, inducible enzyme in hepatocytes [101], 
could help to explain its up-regulation following HCV infection and its role in 
endoplasmic reticulum-derived membranous web formation.  
 
4. Calcium-independent phospholipase A2 
Human calcium-independent phospholipase A2s (iPLA2) constitute a diverse group of 
enzymes, referred to as the group VI in the classification of the PLA2 superfamily of 
enzymes (Table I). As all of the group VI iPLA2 enzymes share a patatin domain, they 
are also referred to as patatin-like phospholipase domain-containing lipases (PNPLA),  
which is perhaps a more suitable denomination, inasmuch as more than a half of the 
enzymes of this group actually exhibit little PLA2 activity [22].  
PNPLA-1 to -5 are enzymes actively involved in the metabolism of LD and the 
development of adipose tissue. These include  PNPLA-2 or adipose TAG lipase, also 
called desnutrin, and PNPLA-3 or adiponutrin. However, as these enzymes exhibit very 
low or no PLA2 activity at all, they will not be further considered in this review. There 
are many recent excellent articles addressing different aspects of these enzymes and the 
interested reader is referred to them for details [102-106]. 
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Group VIA PLA2, or iPLA2β, is the prototypic iPLA2 enzyme. iPLA2β does not 
show any clear substrate preference in in vitro assays, being able to hydrolyze at 
comparable rates all kinds of phospholipids regardless of their fatty acid composition 
[22,107]. This lack of substrate specificity fits well with the originally proposed 
function of the enzyme as a major regulator of phospholipid fatty acyl chain remodeling 
under resting conditions [108-110]. Interestingly, recent results have suggested that 
under activation conditions, iPLA2β may show some selectivity for hydrolyzing PC 
molecules carrying palmitic acid at the sn-1 position [34]. The molecular determinants 
and physiological  implications of this finding  remain to be determined. 
 
4.1. iPLA2β role in LD formation 
iPLA2β has been proposed as a key enzyme for TAG synthesis prior to stress-induced 
LD formation in serum deprived CHO-K1 cells [46]. The enzyme provides 
phospholipid-derived free fatty acids for esterification into neutral lipids [46]. The 
presence of lipid-rich serum in the cell culture medium also induces LDs in these cells, 
but this time in an iPLA2β-independent manner because there is an exogenous source 
free fatty acid [46,52]. This has led to the suggestion that LD formation from 
endogenous lipid sources upon starvation conditions is a cell mechanism to convert 
structural components into energy-rich molecules and store them into LD to boost the 
survival of the cells [20,46,51].  
LD formation under stress conditions also involves participation of cPLA2α (see 
preceding section), and this enzyme appears to act after iPLA2β because both cPLA2α 
activity and AA release depend on an active iPLA2β [46] (Figure 2). These data would 
be in accord with findings that TAG synthesis, mediated by iPLA2β, occurs prior to 
proper LD formation and, in turn, may suggest a regulatory role to iPLA2β beyond that 
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of merely providing free fatty acids for TAG synthesis [46]. It is intriguing to speculate 
with possible mechanisms mediating cross-talk between iPLA2β and cPLA2α. A 
straightforward mechanism for this interplay could be one where products of  iPLA2β 
action on phospholipids regulate, directly or indirectly, cPLA2α activation. For 
example, free fatty acids could directly activate cPLA2α to induce LD formation in 
monocytes [54], and the activation of MAPK-derived signaling, including cPLA2α 
phosphorylation, has been described to lay downstream of iPLA2β activation under 
certain conditions [111]. Coordinate actions of both iPLA2β and cPLA2α in regulating 
cellular signaling leading to LD formation have also recently been suggested in 
macrophages treated with a snake venom PLA2 [48]. 
 
4.2. iPLA2γ role in LD formation 
The other widely-studied member of the iPLA2 family is the group VIB enzyme,  
iPLA2γ. Its localization in peroxisomal and mitochondrial membranes suggests that this 
enzyme may be involved in the integration of lipid and energy metabolism [22]. A brief 
caloric restriction has been reported to induce phospholipid fatty acid turnover and TAG 
accumulation in murine myocardium as a mechanism to supply energy to cells [112]. 
iPLA2γ overexpression in these cells increases both phospholipid fatty acid turnover and 
TAG accumulation after a caloric restriction [113]. Under glucose deprivation, lipids 
are incorporated by cells more efficiently as a mechanism to obtain energy. Because 
iPLA2γ overexpression results in increased mitochondrial phospholipid turnover, these 
organelles appear morphological disrupted, resulting in functional abnormalities. As a 
consequence of this, fatty acids are not efficiently β-oxidized, which leads to their 
storage in cytoplasmic LDs to avoid lipotoxicity [113].  
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5. Secreted Phospholipase A2s 
To date, 11 sPLA2s have been identified in mammals, classified into groups I, II, III, V, 
X and XII (Table I). These enzymes are characterized by a low molecular weight (13-18 
KDa), the requirement of millimolar concentrations of Ca2+ to carry out their catalytic 
activity and the presence of multiple disulfide bonds in their structure [21,22]. Subtle 
differences exist regarding the substrate preference of these enzymes. Thus, some 
enzymes show preference for anionic phospholipids over PC (the group IIA enzyme), 
and vice versa (groups V and X). Regarding fatty acid specificity, the group V enzyme 
seems to prefer oleic acid and linoleic acid chains, group X shows some specificity for 
AA, and group III shows no specificity at all [21,22].  
 
5.1. sPLA2 role in atherosclerosis 
Atherosclerosis is a multifactorial pathology that constitutes the main risk factor for 
cardiovascular disease. Atherosclerosis is characterized by the retention of macrophages 
in the artery wall, and their transformation into foam cells due to the intracellular 
accumulation of lipoprotein-derived neutral lipids, primarily CE, in the form of LDs 
[114]. 
sPLA2s have been found in atherosclerotic lesions, probably originating from the 
monocytes/macrophages, and a role for these enzymes in the emergence and 
progression of the disease has been repeatedly proposed [115,116]. 
From a general point of view, sPLA2 forms may modify native circulating 
lipoproteins through the hydrolysis of their phospholipids, thereby generating free fatty 
acids and lysophospholipids that change the size, electric charge, oxidation 
susceptibility and/or aggregation state of the native lipoprotein particles. These changes 
facilitate their internalization by macrophages, resulting in LD accumulation and foam 
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cell formation by different mechanisms depending on the affinity of sPLA2 enzymes to 
the different substrates. In vitro studies have shown that among all sPLA2s putatively 
involved in atherosclerosis progression, the group X enzyme is the most potent 
hydrolytic enzyme, followed by groups V, and III. Groups IIA, IIE and IIF exhibit low 
rates of hydrolysis of LDL particles [117]. Since PC species are the major phospholipid 
constituents of native LDL particles and the group X, V and III sPLA2s rapidly and 
efficiently hydrolyze this phospholipid, native LDL particles are converted into more 
aggregated small-dense particles because of the reduction in their phospholipid content 
[50,117,118]. These small dense LDL particles present a potent pro-atherogenic 
potential due, in part, to a higher oxidation susceptibility and also to their exposure 
to proteoglycan-binding regions [119], increasing their subendothelial accumulation, 
uptake by macrophages, LD formation and foam cell accumulation.  
On the other hand, the accumulation of large amounts of sPLA2-derived fatty 
acids and lysophospholipids increases the negative electric charge of native LDL 
particles similar to when they become oxidized, and thus the particles acquire an ox-
LDL-like phenotype that could constitute another potential mechanism for sPLA2-
mediated foam cell formation. However, this is a subject of much debate. While ox-
LDL particles have been found to be internalized via scavenger receptors (CD36, SR-A) 
by macrophages [120,121], the involvement of such receptors in sPLA2-modified LDL 
particle internalization is unclear [50,122]. These results, along with the different time-
courses and localizations of internalized of sPLA2-modified versus oxidized LDLs, 
suggest that the change in electric charge of LDL particles following sPLA2 hydrolysis 
could not be of pathophysiological consequence for the accumulation of LDs in 
macrophages. Some studies have been carried out in the presence of albumin to remove 
fatty acids and lysophospholipids from the sPLA2-modified LDL [50,123,124]. This 
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strategy reduced the negative charge of the particles but did not affect LDs 
accumulation [123,124]. Since albumin is abundant in atherosclerotic foci, the electric 
charge of the LDL particles may not change much after sPLA2-catalyzed phospholipid 
hydrolysis under pathophysiologically-relevant settings, which could explain the 
differences in compartmentalization and time-dependent accumulation of neutral lipids 
by macrophages compared with cells exposed to the strongly negatively charged ox-
LDL [120]. 
Group IIA sPLA2 constitutes a special case among sPLA2s because it only 
hydrolyzes a small amount of phospholipids within LDLs due to its preference for 
phospholipids containing anionic head groups [21,22]. Group IIA sPLA2-
overexpressing mice show minimal changes in the phospholipid composition of 
circulating LDLs compared with their wild-type littermates after 8 weeks on a high-fat 
diet [125]. Despite this reduced potential to hydrolyze LDLs compared to other sPLA2s 
[123], group IIA sPLA2 has also been strongly related with atherosclerosis emergence 
and progression [126] due to the involvement of this enzyme in facilitating the 
migration of LDL particles to the subendothelium [117,123]. Group IIA sPLA2 is bound 
to intima proteoglycans [127], and promotes the interaction of ApoB-containing LDL 
with proteoglycans [128], thereby increasing the probability of the particle to undergo 
oxidation and to accumulate in the form of intima-associated ‘extracellular LD’ [129].  
sPLA2-induced hydrolysis of  lipoprotein phospholipids may lead to the release 
of significant amounts of AA [117,118,123]. Among the many biological activities of 
AA, there is its ability to potently induce LD formation in human monocytes [54], 
suggesting a proatherogenic role for AA, which may manifest even before monocyte 
extravasation and differentiation into macrophages has occurred [54,130].  
It is well known that, contrary to LDL, HDL plays a protective role in 
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atherosclerosis, contributing to the reverse efflux of CE from foam cells to their 
degradation in the liver [131]. Groups V and X sPLA2s can hydrolyze phospholipids in 
either HDL or LDL particles at similar rates [117]. Thus the pro-atherogenic role of 
some sPLA2s with regard to LD formation in macrophages could also be explained by 
the decreased reduction of LD levels that macrophages experience when exposed to 
sPLA2-modified HDL instead of native HDL [132]. The cholesterol efflux from 
macrophages to HDL is mediated by the expression of scavenger receptor B type I (SR-
BI) on the surface of macrophages, and its up-regulation induces an increase in the rate 
of CE efflux, resulting in the reduction of LD formation [133]. The presence of  
phospholipids in HDL acceptor particles plays a key role in their CE efflux properties, 
because the more enriched in phospholipid the HDL particle, the better the interaction 
with the SR-BI receptor and hence, the higher the CE efflux [132,133]. Thus, a 
reduction in HDL phospholipid content due to sPLA2 hydrolysis may explain the 
decrease in CE efflux from macrophages. 
Because of the wealth of data suggesting a prominent role for sPLA2s in the 
development and progression of atherosclerosis, pharmacological inhibition of these 
enzymes has been contemplated as a possible therapeutic approach to treating 
cardiovascular disease [116]. Unfortunately, recent trials testing the effect of 
varespladib, an inhibitor of group IIA sPLA2 which most likely also inhibits groups V 
and X, have provided discouraging results. sPLA2 inhibition with this drug did not 
reduce the risk of recurrent recurrent cardiovascular events in patients with acute 
coronary syndrome and actually increased the risk of myocardial infarction [134,135]. 
Clearly, further studies are needed to establish whether targeting the production of 
bioactive lipids via sPLA2 inhibition will have a clinical benefit. 
 
23 
 
5.2. Other sPLA2 roles 
A striking feature of tumor proliferating cells is their lipogenic phenotype, to provide 
building blocks for making new membrane or to supply energy for growth [136,137]. 
These cells also synthesize significant amounts of LDs as a survival mechanism under 
starvation conditions [51]. Some sPLA2 enzymes have been related to cancer 
development by different mechanisms, including the release of AA and the synthesis of 
eicosanoids, and the stimulation of  LD synthesis [138] . 
 Incubation of MDA-MB-231 human breast cancer cells with group X sPLA2 
results in increased LD formation by a mechanism that fully depends on the activity of 
the enzyme [51]. These cells also show up-regulation of their β-oxidation related genes 
and repression of the de novo lipogenesis genes [51]. This is in accordance with other 
studies showing that the sole overexpression of group X sPLA2 results in reduced TAG 
levels in cultured pre-adipocyte cells, and decreased transcription of genes encoding for 
lipogenic proteins such as SREBP-1c, fatty acid synthase or PPARγ [139]. Inhibition of 
fatty acid β-oxidation with etomoxir reduces LD formation in response to group X 
sPLA2, highlighting the seemingly odd circumstance that anabolic –neutral lipid 
formation and storage in LD– and catabolic –β-oxidation of fatty acids– processes take 
place simultaneously. Thus, fatty acids released by the action of group X sPLA2 on 
membranes can follow two opposite routes, and the proposal has been made that one 
route may serve to support the other, e.g. fatty acid β-oxidation products such as ATP or 
NADPH could be needed to support LD biogenesis [20,51]. 
The group XII of the PLA2 family consists of two members, XIIA and XIIB. 
Both PLA2s have the same sequence except for the fact that the active site His in group 
XIIA is replaced with Leu in Group XIIB, which makes the later catalytically inactive 
[21,22]. In spite of this, group XIIB sPLA2, which is quite abundant in hepatocytes, 
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appears to play a prominent role in regulating LD size and number in these cells 
[140,141]. By acting downstream of the transcription factor hepatocyte nuclear factor-
4α (HNF-4α), group XIIB sPLA2 regulates VLDL secretion from the liver to the 
bloodstream. Down-regulation of the enzyme results in reduced VLDL secretion and the 
accumulation of TAG in the form of LDs into hepatocytes, leading to a fatty liver 
phenotype as well as the concomitant decrease in circulating HDL, LDL and TAG 
levels. In the group XIIB sPLA2
-/- mice, the genes encoding for fatty acid synthase and 
stearoyl-CoA desaturase-1 appear down-regulated, perhaps as a response to the 
excessive accumulation of LDs in the hepatocytes of these mice [141].  
 
6. Roles of other Phospholipases A2 
PAF acetyl hydrolases are a group of PLA2s which hydrolyze acetate from the sn-2 
position of PAF, releasing acetic acid and 1-O-alkyl-PC (i.e. lyso-PAF). To date, four of 
these enzymes have been described, and one of them, group VIIA PLA2, also known as 
Ca2+-independent secreted PAF acetyl hydrolase, or lipoprotein-associated PLA2 (Lp-
PLA2), has been related with foam cell formation [142]. In addition to PAF, this enzyme 
also hydrolyzes phospholipids containing a short-chain oxidized fatty acid at the sn-2 
position [21,22]. 
In some studies, an anti-atherogenic function for Lp-PLA2 has been assigned 
through the reduction of early foam cell formation in blood vessels. Lp-PLA2 
overexpression protects HDL and LDL from oxidation, on one hand converting LDL to 
a less proatherogenic particle and, on the other hand, preventing the reduction of the 
HDL-mediated CE reverse efflux transport from macrophages [132]. This results in the 
reduction of foam cell formation and atherosclerosis injury in in vivo models [143]. 
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Moreover, foam cell formation in RAW264.7 macrophages is also decreased when the 
cells are incubated with ox-LDL particles that contain Lp-PLA2 activity. Inhibition of 
the Lp-PLA2 activity associated to the particles leads to increased foam cell formation 
[144]. 
On a different view,  the products of  Lp-PLA2 action on lipoprotein phospholipids, 
lysoPC and oxidized fatty acids, are both well established proinflammatory mediators. 
Accordingly, and despite the protective role that this enzyme appears to exert on foam 
cell formation, a predominant pro-atherogenic role has been assigned to this enzyme 
owing to its ability to generate pro-inflammatory substances which may contribute to 
atherosclerosis progression by several mechanisms [142,145]. The presence of this 
enzyme in plasma has been deemed as a marker of coronary risk [146]. The 
pharmaceutical industry has developed a number of reversible inhibitors for this enzyme 
and one of them, darapladib, has been tested in clinical trials in humans with 
discouraging results [147]. 
Group XV PLA2 or lysosomal PLA2 hydrolyzes PC and PE substrates under acidic 
conditions in a Ca2+-independent manner [21,22,148]. This enzyme is highly expressed 
in alveolar macrophages and contributes to the metabolism of the pulmonary surfactant 
[148]. Macrophages from mice lacking group XV PLA2 present a massive accumulation 
of phospholipids in the form of lamellar body inclusions, indicative of cellular 
phospholipidosis [148]. Phospholipidosis is related with a foam cell phenotype similar 
to that of macrophages challenged with ox-LDL. According with the protective role of 
group XV PLA2 in foam cell formation, mice lacking this enzyme develop more severe 
lesions than their wild type littermates in a model of atherosclerosis [148]. 
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7. Concluding remarks 
The interest for LDs is rapidly increasing but still little is known about the mechanisms 
governing their formation. The studies discussed in this article regarding the 
involvement of PLA2s constitute a starting point for a detailed understanding of 
molecular mechanisms and participating pathways. Clearly, this is a very complex issue 
involving multiple enzymes, and there is still much to be learned about the interplay 
between some of the participant PLA2 enzymes and the regulatory processes involved.  
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Figure Legends 
Figure 1. LD synthesis from the cytosolic face of the smooth endoplasmic reticulum 
membranes. The essential role of cPLA2α role in inducing a positive membrane 
curvature is indicated in step 3. Lysophospholipids are highlighted in pink, and 
phosphatidic acid in green. All other phospholipids are shown in blue. For further 
details see text. 
 
Figure 2. Sequential role of PLA2 forms in LD formation. iPLA2 regulates neutral lipid 
synthesis first; then, cPLA2α regulates formation of the organelle itself. Whether there 
is cross-talk between the two PLA2s is not known. For details see text. 
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TABLE I - PLA2 Classification and Roles in LD Formation  
  
Group Subgroup Trivial name MW 
(kDa) 
Type of enzyme Other catalytic activities Role in LD formation Ref. 
I A - 13 - 15 Secreted, Ca2+ dependent - - - 
 B Pancreatic PLA2 13 - 15 Secreted, Ca
2+ dependent - - - 
II A - 13 - 15 Secreted, Ca2+ dependent - EA: Promotes LD formation 
OE: Induces foam cell formation 
48 
125 
 B - 13 - 15 Secreted, Ca2+ dependent Inactive - - 
 C - 15 Secreted, Ca2+ dependent - - - 
 D - 14 - 15 Secreted, Ca2+ dependent - - - 
 E - 14 - 15 Secreted, Ca2+ dependent - - - 
 F - 16 - 17 Secreted, Ca2+ dependent - - - 
III - - 15-18; 
55 
Secreted, Ca2+ dependent - OE: Promotes foam cell 
formation 
117 
IV A cPLA2α  85 Cytosolic, Ca
2+ dependent Lysophospholipase,  
transacylase  
KD: decreases LD formation 20, 46, 52 
53 
B cPLA2β 114 Cytosolic, Ca
2+ dependent - - - 
C cPLA2γ 64 Cytosolic, Ca
2+ dependent Lysophospholipase - - 
D cPLA2δ 91 Cytosolic, Ca
2+ dependent - - - 
E cPLA2ε 95 Cytosolic, Ca
2+ dependent - - - 
F cPLA2ζ 95 Cytosolic, Ca
2+ dependent - - - 
V   14 Secreted, Ca2+ dependent - EA: Promotes foam cell 
formation 
50, 124 
VI A iPLA2, iPLA2β 88-90 Ca
2+ independent PLA1, lysophospholipase, 
PAF acetylhydrolase, and 
transacylase 
OE: Accumulation of TAG in 
myocardium. 
113 
 
 B iPLA2γ 88 Ca
2+ independent - - - 
        
VII A PAF-AH (lipoprotein 
associated PLA2) 
45 Secreted, Ca2+ independent Lipase, esterase and  
transacetylase  
OE: Attenuation of foam cell 
formation. 
144 
 B PAF-AH (II) 40 Intracellular, Ca2+ independent  - - 
VIII A PAF-AH Ib (α1) 26 Ca2+ independent - - - 
 B PAF-AH Ib  (α2) 26 Ca2+ independent - - - 
IX - Conodipine-M 14 Secreted, Ca2+ dependent - - - 
X - - 14 Secreted, Ca2+ dependent - EA: promotes foam cell 
formation. 
EA/OE: induces LD formation. 
49, 118 
 
51 122 
XI A - 12.4 Secreted, Ca2+ dependent - - - 
 B - 12.9 Secreted, Ca2+ dependent - - - 
XII A - 19 Secreted, Ca2+ dependent - - - 
 B - 19.7 Secreted, Ca2+ dependent Inactive KO: Increases hepatic TAG 140 
XIII - - <10 Secreted, Ca2+ dependent - - - 
XIV - - 13-19 Secreted, Ca2+ dependent - - - 
XV  Lysosomal PLA2 45 Lysosomal, Ca
2+ independent Transacylase KO: Foam cell formation 148 
XVI  Adipose-specific PLA2 18 Ca
2+ dependent/ 
Independent 
PLA1 -  
 
*KO: Knock out; KD: Knock down (siRNA); OE: Overexpression; EA: External addition  
 
 
